Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,302.00+2.25%ETH$2,418.52+3.76%GOLD$4,146.50+1.80%OIL$89.03+1.03%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMRN

Immuron Limited

Healthcare · Biotechnology

$0.85

Down-$0.01 (-0.84%)

Updated Nov 5, 2026, 11:58 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.09M
P/E ratio
-1.74
Dividend yield
0.00%
52-week range
$0.70 – $1.99
Volume
18.33K
Avg. volume
545.45K

Price performance · IMRN

IMRN price history

1M range · 0 trading sessions · Daily adjusted prices

IMRN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IMRN news

The latest Smart Investors Daily articles mentioning IMRN.

Stock researchCompany · Overview

IMRN research

Overview

Company profile and research snapshot.

Company profile

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
IMRN recent ratings
DateFirmRatingTarget
Oct 18, 2017H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Immuron continued quarterly sales growth

Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp)Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp)Q1 sales up 12% on prior quarter Canada Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp)Q1 sales up 63% on prior quarter USA Q1 sales AUD$0.3 million down 19% on prior comparative period (pcp)Q1 sales down 24% on prior quarter MELBOURNE, Australia, Oct. 27, 2026 (GLOBE NEWS

Yahoo · Oct 22, 2026

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm – 4:55pm U.S. Eastern Time). Please submit your questions in advance to [email protected] or ask your questions during the event. Please register here to ensure you are able to attend the conference and receive any updates that

Yahoo · Oct 13, 2026

Travelan® Phase 2 Study Results Published

MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the prevention of Travellers' Diarrhoea," describes c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By